NYRADA INC. (ASX:NYR) 18 Financial summary Nyrada maintained disciplined capital and cost management throughout the financial year while ensuring its clinical and research programs remained fully funded. In August 2025 the Company completed a placement to new and existing institutional, sophisticated and professional investors, raising $8.25 million before costs at an issue price of $0.30 per CHESS Depositary Interest ('CDI'). Of that amount, $0.09 million was received from Non-executive Director participation on the same terms, following CDI holder approval at the November 2025 Annual General Meeting. A further $2.29 million was received during the year on the exercise of options, including $0.60 million from Director option exercises in December 2025. In May 2026 the Company received a cash reimbursement of $2.45 million under the Australian Government's Research and Development Tax Incentive in respect of the financial year ended 30 June 2025. Cash and cash equivalents at 30 June 2026 were $8.38 million, compared with $2.93 million at 30 June 2025, an increase of $5.46 million over the year. Liquidity and capital resources Nyrada ended the financial year with cash and cash equivalents of $8,384,581 and anticipates receiving a Research and Development tax incentive refund of approximately $1,720,573 for FY2026 following 30 June 2026, thus further boosting working capital resources in FY2027. Matters subsequent to the end of the financial year On 6 July 2026, the Consolidated Entity announced that it had commenced patient dosing in its Phase IIa PROTECT-MI clinical trial and continued progress with clinical trial site activations and recruitment activities. No other matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect the Consolidated Entity's operations, the results of those operations, or the Consolidated Entity's state of affairs in future financial years. Future developments, prospects, and business strategies Disclosure of information regarding likely developments in the operations of the Company in future financial years and the expected results of those operations is likely to result in unreasonable prejudice to the Company. Information on future developments, prospects, and business strategies have only been referred to in the Chair’s Letter and CEO Report. For further information on the Company’s business strategies and material risks, refer also to the Prospectus which is available on the Company website or ASX Announcements. Environmental regulation The Consolidated Entity is not subject to any significant environmental regulation under Australian Commonwealth or State law. Directors’ shareholdings In this section, reference is made to Share ownership. The instruments registered for trade on the Australian Securities Exchange are CDIs. One CDI is equivalent to one Share, being Class A Common Stock. The following table sets out each director’s relevant interest in shares, debentures, and rights or options in shares or Directors of the Company or a related body corporate as at the date of this report: Share Number Options Number John Moore 9,491,756 3,600,000 Rüdiger Weseloh 1,483,332 1,800,000 Marcus Frampton 3,211,740 1,800,000 Christopher Cox 2,025,000 1,800,000 Ian Dixon 9,780,699 1,800,000 James Bonnar 1,225,989 5,000,000
RkJQdWJsaXNoZXIy MjE2NDg3